Efficacy and safety of olezarsen in lowering apolipoprotein C-III and triglycerides in healthy Japanese Americans
Single- and multiple-dose administration of olezarsen was safe, was well tolerated, and significantly reduced apoC-III and triglyceride levels in healthy Japanese Americans.
Authors
- Angelika Hoenlinger
- Jing‐He Yan
- Anastasia Lesogor
- Alison Margolskee
- Ewa Karwatowska‐Prokopczuk (ORCID: https://orcid.org/0000-0002-6371-5834)
- Sotirios Tsimikas (ORCID: https://orcid.org/0000-0001-9834-9494)
- Lu Li (ORCID: https://orcid.org/0000-0003-1643-1684)
Institutions
- Novartis (Switzerland) (CH)
- Ionis Pharmaceuticals (United States) (US)
- University of California San Diego (US)
Publication Details
- Journal
- Lipids in Health and Disease
- Published
- 2024-10-03
- DOI
- https://doi.org/10.1186/s12944-024-02297-5
- Citations
- 13
- Primary Topic
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Type
- article
- Field-Weighted Citation Impact
- 4.65
Funders
- Ionis Pharmaceuticals